

2021 Medicare Part B Step Therapy Drug List

- Step therapy requires a trial of a preferred drug to treat a medical condition before covering other drug therapies.
- The step therapy requirement does not apply to members who have already received treatment with the non-preferred drug within the past 365 days.
- These drugs may also be subject to prior authorization and/or quantity limitations.

Drug Class	Drug Products Requiring Step Therapy
Acromegaly	Sandostatin LAR Depot Signifor LAR Somavert
Adrenocorticotrophic Hormone Analogue	Acthar
Alpha-1 Antitrypsin Deficiency	Aralast Glassia Zemaira
Autoimmune	Actemra Arcalyst Avsola Cimzia Entyvio Ilaris Ilumya Inflectra Ixifi Orencia Remicade Renflexis Simponi Aria Stelara
Bevacizumab	Avastin
Bone Density Regulators	Prolia Reclast Zoledronic Acid Zometa

Drug lists are subject to change and will be updated at least 30 days prior to the effective date

Publish Date: 09/2021

Effective Date: 10/2021

Drug Class	Drug Products Requiring Step Therapy
Botulinum Toxins	Botox Myobloc
Chimeric Antigen Receptor Therapy	Yescarta Tecartus Kymriah
Growth Hormones	Genotropin Humatrope Norditropin Nutropin Onitope Saizen Zomacton Zorbitive
Gout Therapy	Krystexxa
Hematologic, Erythropoiesis – Stimulating Agents (ESA)	Epogen Mircera Procrit
Hematologic, Neutropenia Colony Stimulating Factors – Long Acting	Neulasta syringe
Hematologic, Neutropenia Colony Stimulating Factors – Short Acting	Granix Leukine Neupogen
Hereditary Angioedema (HAE) Prophylaxis	Cinryze Takhzyro
Homozygous Familial Hypercholesterolemia (HoFH)	Evkeeza
Iron Products	Feraheme Injectafer
Lipodystrophy	Myalept

Drug lists are subject to change and will be updated at least 30 days prior to the effective date

Publish Date: 09/2021

Effective Date: 10/2021

Drug Class	Drug Products Requiring Step Therapy
Lysosomal Storage Disorders – Gaucher Disease	Cerezyme VPRIV
Migraine Therapy	Vyepti
Monoclonal Antibodies – Asthma	Cinqair Fasenra Nucala Xolair
Monoclonal Antibody – Other	Enspryng Soliris Tepezza Uplizna
Multiple Sclerosis (Infused)	Lemtrada
Osteoarthritis, Viscosupplements – Single Injection	Durolane Gel-One Monovisc Supartz Supartz FX
Osteoarthritis, Viscosupplements – Multi Injection	Euflexxa Gelsyn-3 Genvisc 850 Hyalgan Hymovis Supartz Supartz FX Trivisc Visco-3
Prostate Cancer – Luteinizing Hormone Releasing Hormone (LHRH) Agents	Lupron Depot Trelstar Zoladex
Pulmonary Arterial Hypertension (PAH)	Remodulin Tyvaso

Drug lists are subject to change and will be updated at least 30 days prior to the effective date

Publish Date: 09/2021

Effective Date: 10/2021

Drug Class	Drug Products Requiring Step Therapy
Retinal Disorders Agents	Beovu Eylea Lucentis Macugen Visudyne
Rituximab	Rituxan
Sickle Cell Therapy	Adakveo
Systemic Lupus Erythematosus (SLE) Agent	Benlysta
Trastuzumab	Herceptin

Drug lists are subject to change and will be updated at least 30 days prior to the effective date

Publish Date: 09/2021

Effective Date: 10/2021

Gateway HealthSM complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Gateway Health does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

ENGLISH

ATTENTION: If you speak English, language assistance services, free of charge, are available to you. Call 1-800-685-5209, (TTY: 711).

SPANISH

ATENCIÓN: Si usted habla español, tenemos servicios de asistencia lingüística disponibles para usted sin costo alguno. Llame al 1-800-685-5209, (TTY: 711).

CHINESE

小贴士：如果您说普通话，欢迎使用免费语言协助服务。请拨 1-800-685-5209, (TTY: 711).